Clinical characteristics of women with HIV in the RESPOND cohort: A descriptive analysis and comparison to men
J. Hutchinson,B. Neesgard,J. Kowalska,K. Grabmeier‐Pfistershammer,M. Johnson,K. Kusejko,S. De Wit,F. Wit,C. Mussini,A. Castagna,M. Stecher,C. Pradier,P. Domingo,C. Carlander,J. Wasmuth,N. Chkhartishvili,V. Uzdaviniene,A. Haberl,A. d'Arminio Monforte,H. Garges,J. Gallant,M. Said,B. Schmied,M. van der Valk,D. Konopnicki,N. Jaschinski,A. Mocroft,L. Greenberg,F. Burns,L. Ryom,K. Petoumenos
DOI: https://doi.org/10.1111/hiv.13662
2024-06-07
HIV Medicine
Abstract:Background Women with HIV are globally underrepresented in clinical research. Existing studies often focus on reproductive outcomes, seldom focus on older women, and are often underpowered to assess sex/gender differences. We describe CD4, HIV viral load (VL), clinical characteristics, comorbidity burden, and use of antiretroviral therapy (ART) among women with HIV in the RESPOND study and compare them with those of the men in RESPOND. Methods RESPOND is a prospective, multi‐cohort collaboration including over 34 000 people with HIV from across Europe and Australia. Demographic and clinical characteristics, including CD4/VL, comorbidity burden, and ART are presented at baseline, defined as the latter of 1 January 2012 or enrolment into the local cohort, stratified by age and sex/gender. We further stratify men by reported mode of HIV acquisition, men who have sex with men (MSM) and non‐MSM. Results Women account for 26.0% (n = 9019) of the cohort, with a median age of 42.2 years (interquartile range [IQR] 34.7–49.1). The majority (59.3%) of women were white, followed by 30.3% Black. Most women (75.8%) had acquired HIV heterosexually and 15.9% via injecting drug use. Nearly half (44.8%) were receiving a boosted protease inhibitor, 31.4% a non‐nucleoside reverse transcriptase inhibitor, and 7.8% an integrase strand transfer inhibitor. The baseline year was 2012 for 73.2% of women and >2019 for 4.2%. Median CD4 was 523 (IQR 350–722) cells/μl, and 73.6% of women had a VL <200 copies/mL. Among the ART‐naïve population, women were more likely than MSM but less likely than non‐MSM (p
infectious diseases